文献速递妇科

接受孕激素治疗的年轻子宫内膜癌患者全因死亡率

All-cause mortality in young women with endometrial cancer receiving progesterone therapy.
PubMed 文献 · Am J Obstet Gynecol · 2017-08-24

激素治疗使用率从2004年的2.4%升至2014年的5.9%,且与全因死亡率升高相关(HR 1.92,95%CI 1.15-3.19),在IB期患者中尤为明显。

要点

  • 年轻I期子宫内膜癌患者激素治疗使用率从2004年2.4%升至2014年5.9%。
  • 激素治疗组5年生存率96.4%,低于子宫切除术组的97.2%。
  • 多变量模型中激素治疗与死亡风险升高相关(HR 1.92,95%CI 1.15-3.19)。

核心结论

  • 孕激素治疗的使用正在增加,其使用与生存率下降相关,尤其在IB期肿瘤患者中。

主要发现

  • 激素治疗使用率从2004年的2.4%(95%CI 1.8-3.3%)上升至2014年的5.9%(95%CI 5.0-6.9%)(P<.0001)。
  • 激素治疗使用率随年龄增大、亚分期升高和分级升高而降低;黑人女性更可能接受激素治疗,而医疗补助(Medicaid)受助者更不可能接受激素治疗。
  • 激素治疗组5年生存率为96.4%(95%CI 94.3-98.0%),子宫切除术组为97.2%(95%CI 96.9-97.4%)。
  • 多变量模型中,接受激素治疗的女性死亡风险是接受初次子宫切除术女性的1.92倍(HR 1.92;95%CI 1.15-3.19)。
  • 按分期分层,激素治疗与IB期和I期非特指型肿瘤患者死亡率升高相关,但与IA期肿瘤无此关联。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Uterine-preserving therapy with progesterone may be used in young women with endometrial cancer who desire fertility preservation. Such therapy delays definitive treatment with hysterectomy. OBJECTIVE: We examined the use and safety of progestational therapy in young women with endometrial cancer. The primary outcome of the analysis was overall survival. STUDY DESIGN: We identified women ≤49 years of age with stage I endometrial cancer in the National Cancer Database from 2004 through 2014. Women treated with hormonal therapy with or without hysterectomy were compared to women treated with hysterectomy. After propensity score weighting, overall survival was examined using proportional hazards models. RESULTS: A total of 23,231 patients, including 872 (3.8%) women treated with hormonal therapy were identified. Use of hormonal therapy was 2.4% (95% confidence interval, 1.8-3.3%) in 2004 and increased over time to 5.9% (95% confidence interval, 5.0-6.9%) by 2014 (P < .0001). Use of hormonal therapy decreased with older age, higher substage, and increasing grade. Black women were more likely to receive hormonal therapy while Medicaid recipients were less likely to receive hormonal therapy. The 5-year survival for patients treated with hormonal therapy was 96.4% (95% confidence interval, 94.3-98.0%) compared to 97.2% (95% confidence interval, 96.9-97.4%) for hysterectomy. In a multivariable model, women treated with hormonal therapy were 92% (hazard ratio, 1.92; 95% confidence interval, 1.15-3.19) more likely to die compared to women who underwent primary hysterectomy. When stratified by stage, hormonal therapy was associated with increased mortality in women with stage IB and I-not otherwise specified tumors but not for stage IA neoplasms. CONCLUSION: Use of progestational therapy is increasing. Its use was associated with decreased survival, particularly in women with stage IB tumors.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Ruiz MP, Huang Y, Hou JY, et al. All-cause mortality in young women with endometrial cancer receiving progesterone therapy. Am J Obstet Gynecol. 2017. PMID: 28844824. doi:10.1016/j.ajog.2017.08.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。